Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company won FDA approval for Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company won FDA approval for Abilify.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company won FDA approval for Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
Get the most out of
Register for free and enjoy unlimited access to: